Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor

22 Jun 2018

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 29937315
DOI: 10.1016/j.ygyno.2018.05.028

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitorPMID 29937315Read ↗

PARP inhibitors: Clinical utility and possibilities of overcoming resistanceSemantic proximity Read ↗

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?Semantic proximity Read ↗

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)Semantic proximity Read ↗

PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?Semantic proximity Read ↗

PARPis after PARPis in patients with recurrent epithelial ovarian cancer: A single institutional experienceSemantic proximity Read ↗

Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”Semantic proximity Read ↗

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group studySemantic proximity Read ↗

PARP Inhibitors in Endometrial Cancer: Current Status and PerspectivesSemantic proximity Read ↗

Case report: Response with chemotherapy and Olaparib in a patient with advanced cervical adenocarcinomaSemantic proximity Read ↗

First-line PARP inhibition in ovarian cancer - standard of care for all?Semantic proximity Read ↗

Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial CancerSemantic proximity Read ↗

Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.